Skip to content

Executive and social functioning in patients with Tyrosinemia Type 1

Executive and social functioning in patients with Tyrosinemia Type 1 - Executive and social functioning in Tyrosinemia Type 1

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
NL-OMON
Registry ID
NL-OMON47045
Enrollment
36
Registered
2012-08-28
Start date
2012-08-30
Completion date
Unknown
Last updated
2024-04-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Metabolic disease Tyrosinemia Type 1

Interventions

None listed

Sponsors

Universitair Medisch Centrum Groningen
Lead Sponsor

Eligibility

Age
2 Years to 99 Years

Inclusion criteria

Inclusion criteria: General inclusion criteria for recruitment of HT1 patients: - Patients meet NIH-diagnostic criteria for Hereditary Tyrosinemia Type 1 (HT1) - Patients are treated with NTBC alone or with a diet as well, or patients received orthotopic liver transplantation (OLT) - Minimum age of 7 years at time of study - IQ >= 80 (if unknown, this will be assessed) - Patients have not participated in neuropsychological studies in the last 6 months - Native speaker;General inclusion criteria for recruitment of controls: - Controls are healthy - Minimum age of 7 years at time of study - IQ >= 80 (if unknown, this will be assessed) - Controls have not participated in neuropsychological studies in the last 6 months - Native speaker

Exclusion criteria

Exclusion criteria: General exclusion criteria for recruitment of HT1 patients: - Mental retardation that has been diagnosed by the clinical centre - Neurological damage due to the disease, except for acute porphyria attacks - Medical illnesses other than HT1 with known effects on cognitive and social functioning - Not a native speaker;General exclusion criteria for recruitment of controls: - Mental retardation that has been diagnosed by the clinical centre - Medical illnesses with known effects on cognitive and social functioning - Not a native speaker

Design outcomes

Primary

MeasureTime frame
Main study parameters/endpoints: Neurocognitive tasks, measuring executive functions (inhibition, working memory, cognitive flexibility) and social cognition serve as study parameters. Questionnaires measuring executive and social functioning and behaviour in daily life are also used. Historical and concurrent tyrosine and phenylalanine concentrations are used as predictors expecting significant differences between HT1 patients with high and low blood levels, and between patients and controls.

Secondary

MeasureTime frame
Participants will perform an abbreviated version of the Wechsler Intelligence Scale for Children (WISC) and Wechsler Adult Intelligence Scale (WAIS) with two subtests: Block Design and Vocabulary. Next to this timing and clinical symptoms at time of diagnosis and some bloodresults will be gathered namely (all other amino acids (including tryptophan), succinylacetone and NTBC concentration, serotonine, prolactin and metanephrines (breakdown of noradrenaline and adrenaline))

Countries

Netherlands

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)